

Fenoflox 50 mg/ml Solution for Injection for Cattle, Pigs, Dogs and Cats

Authorised

- Enrofloxacin

Product identification

Medicine name:

Fenoflox 50 mg/ml Solution for Injection for Cattle, Pigs, Dogs and Cats

Fenoflox 50 mg/ml Solution for Injection for Cattle, Pigs, Dogs and Cats

Active substance:

Enrofloxacin

Target species:

Pig

Cattle

Dog

Cat

Route of administration:

Intramuscular use

Intravenous use

Subcutaneous use

Product details

Active substance and strength:

Enrofloxacin

50.00 milligram(s) / 1.00 millilitre(s)

Pharmaceutical form:

Solution for injection

Withdrawal period by route of administration:

Intramuscular use:

-

Pig

- Meat and offal. 13 day

Intravenous use:

-

Cattle

- Meat and offal. 5 day

Subcutaneous use:

-

Cattle

- Meat and offal. 12 day

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QJ01MA90

Legal status of supply:

Veterinary medicinal product subject to veterinary prescription

Authorisation status:

Valid

Authorised in:

Ireland

Package description:

Container material: Type I Amber Glass
Container closure: Grey teflonised chlorobutyl rubber stopper with an aluminium cap
Container colour: Amber
Container volume: 250 ml
No. of containers in a carton: 20 x 250 ml

Container material: Type I Amber Glass
Container closure: Grey teflonised chlorobutyl rubber stopper with an aluminium cap
Container colour: Amber
Container volume: 250 ml
No. of containers in a carton: 15 x 250 ml

Container material: Type I Amber Glass
Container closure: Grey teflonised chlorobutyl rubber stopper with an aluminium cap
Container colour: Amber
Container volume: 250 ml
No. of containers in a carton: 12 x 250 ml

Container material: Type I Amber Glass
Container closure: Grey teflonised chlorobutyl rubber stopper with an aluminium cap
Container colour: Amber
Container volume: 250 ml
No. of containers in a carton: 10 x 250 ml

Container material: Type I Amber Glass
Container closure: Grey teflonised chlorobutyl rubber stopper with an aluminium cap
Container colour: Amber
Container volume: 250 ml
No. of containers in a carton: 5 x 250 ml

Container material: Type I Amber Glass
Container closure: Grey teflonised chlorobutyl rubber stopper with an aluminium cap
Container colour: Amber
Container volume: 250 ml
No. of containers in a carton: 1 x 250 ml

Container material: Type I Amber Glass
Container closure: Grey teflonised chlorobutyl rubber stopper with an aluminium cap
Container colour: Amber
Container volume: 100 ml
No. of containers in a carton: 20 x 100 ml

Container material: Type I Amber Glass
Container closure: Grey teflonised chlorobutyl rubber stopper with an aluminium cap
Container colour: Amber
Container volume: 100 ml
No. of containers in a carton: 15 x 100 ml

Container material: Type I Amber Glass
Container closure: Grey teflonised chlorobutyl rubber stopper with an aluminium cap
Container colour: Amber
Container volume: 100 ml
No. of containers in a carton: 12 x 100 ml

Container material: Type I Amber Glass
Container closure: Grey teflonised chlorobutyl rubber stopper with an aluminium cap
Container colour: Amber
Container volume: 100 ml
No. of containers in a carton: 10 x 100 ml

Container material: Type I Amber Glass
Container closure: Grey teflonised chlorobutyl rubber stopper with an aluminium cap
Container colour: Amber
Container volume: 100 ml
No. of containers in a carton: 5 x 100 ml

Container material: Type I Amber Glass
Container closure: Grey teflonised chlorobutyl rubber stopper with an aluminium cap
Container colour: Amber
Container volume: 100 ml
No. of containers in a carton: 1 x 100 ml

Additional information

Entitlement type:

Marketing Authorisation

Marketing authorisation holder:

Chanelle Pharmaceuticals Manufacturing Limited

Marketing authorisation date:

14/05/2010

Manufacturing sites for batch release:

Labiana Life Sciences S.A.

Chanelle Pharmaceuticals Manufacturing Limited

Responsible authority:

Health Products Regulatory Authority

Authorisation number:

VPA10987/072/001

Date of authorisation status change:

14/05/2010

Reference member state:

Ireland

Procedure number:

IE/V/0223/001

Concerned member states:

Austria Belgium Cyprus Czechia Finland France Germany Hungary Italy
Luxembourg Portugal Slovakia United Kingdom (Northern Ireland)

To consult adverse reactions on veterinary medicinal products please go to
www.adrreports.eu/vet